Remove 2018 Remove Communication Remove Documentation Remove Pharmaceutical Companies
article thumbnail

Navigating Life Sciences Construction in California

ISPE

It's no wonder that global pharmaceutical companies are increasingly sourcing innovation through alliances and partnerships with their peers in California. California accounted for 15–18% of patents granted in core life sciences applications between 2018 and 2022.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website. Four of the five staffers originally involved in the investigation now work for or lobby for the pharmaceutical industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceutical company engagement during the crisis. The answer was yes.

article thumbnail

Removing Regulatory Hurdles for Continuous Pharmaceutical Manufacturing

ISPE

For example, one pharmaceutical company that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. Pharmaceutical Engineering no. 38 (May/June 2018): 40–41. March 2023.

FDA 52
article thumbnail

An Evaluation of Postapproval CMC Change Timelines

ISPE

link] 3 a b International Federation of Pharmaceutical Manufacturers and Associations. Published November 2018. link] 4 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Pharmaceutical Engineering 42, no. link] 6 International Pharmaceutical Regulators Programme.